VERU - Veru leads Cantor's biopharma stocks with largest increases in short interest

Citing up to date short interest data as of Apr. 26, Cantor Fitgerald points out that the oncology-focused biopharmaceutical company Veru (NASDAQ:VERU) had the biggest jump in short interest under its coverage with a ~279% increase. Miami, Florida-based Veru (VERU) added more than 25% of value on Monday after disclosing Phase 2 results for the company’s oral COVID-19 drug sabizabulin in patients who are at high risk for acute respiratory distress syndrome (ARDS). In addition, Cantor listed Narcan maker Opiant Pharmaceuticals (OPNT) and Merck (MRK) as other pharma stocks with large increases in short interest with ~68% and ~14% gains, respectively. Meanwhile, Heron Therapeutics (HRTX) and Omeros (OMER) were included as the pharma stocks with highest short floats with ~38% and ~19% shares floated compared to total shares in the flat, respectively. Read about which pharma stocks dominated the list two weeks ago.

For further details see:

Veru leads Cantor’s biopharma stocks with largest increases in short interest